Events | 2009.11.02
Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD), in collaboration with GlaxoSmithKline (GSK), today announced plans for an international, event-driven (morbidity and mortality) clinical trial to study combination therapy versus monotherapy in a first-line treatment setting for pulmonary arterial hypertension (PAH). The study, AMBITION (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in subjects with pulmonar
For more information, please visit
http://www.businesswire.com/news/home/20091102005344/en
